Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Antagonists on Residual Renal Function Preservation in Peritoneal Dialysis Patients

Abstract

Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARBs) are recommended in peritoneal dialysis (PD) patients for hypertension or heart failure control [1] Angiotensin II (AII) is an important factor in the development of renal fibrosis due to its hemodynamic effects on glomeruli and stimulation of extracellular matrix proteins synthesis, mediated by TGF b [2]. This may explain why treatment with ACEi and ARBs is renoprotective in patients with diabetic and non-diabetic nephropathy.